Myovant closer to US market with pill-a-day prostate cancer drug

23 June 2020

The share price of Myovant Sciences (NYSE: MYOV) was 7% higher minutes ahead of the opening of US markets on Tuesday.

This came amid the news that once-daily, oral relugolix (120mg), for the treatment of men with advanced prostate cancer, has been accepted for Priority Review by the US Food and Drug Administration (FDA).

Lynn Seely is chief executive of Myovant, which is majority-owned by Japanese pharma company Sumitomo Dainippon Pharma (TYO: 4506).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK